Comparative Analysis of Antimicrobial Resistance Patterns in Humans and Animals: A One Health Perspective

Anya Sharma; Ben Carter; Chandra Gupta; Sofia Petrova

Comparative Analysis of Antimicrobial Resistance Patterns in Humans and Animals: A One Health Perspective

Authors: Anya Sharma, Ben Carter, Chandra Gupta, Sofia Petrova

Journal: Journal of One Health and Zoonotic Diseases (JOHZD), ISSN 3155-9565

Citation: JOHZD 1(1), 2024-02-29.

Type: Original Research

Abstract

The escalating global crisis of antimicrobial resistance (AMR) necessitates a comprehensive understanding of its transmission pathways across different species and environments. This study presents a comparative analysis of AMR patterns observed in human and animal populations, employing a One Health framework. We synthesized data from various surveillance programs and published literature to identify common resistance trends, specific resistant bacterial strains, and the potential for interspecies transmission. Our findings highlight significant overlaps in resistance profiles for key bacterial pathogens, such as Escherichia coli and Salmonella, across human, livestock, and companion animal sectors. The prevalence of certain resistance genes and mechanisms, like extended-spectrum beta-lactamases (ESBLs), appears to be driven by shared antimicrobial usage patterns and environmental contamination. A detailed examination of specific antimicrobial classes reveals differential resistance development in various hosts, influenced by distinct therapeutic and agricultural applications. The analysis underscores the critical role of agricultural practices and veterinary medicine in shaping the AMR landscape that impacts human health. We conclude that a coordinated, interdisciplinary approach is paramount to effectively mitigate AMR, emphasizing enhanced surveillance, responsible antimicrobial stewardship in both human and animal health, and improved infection prevention and control measures across all sectors. This integrated strategy is essential to preserve the efficacy of antimicrobials for future generations.

Keywords

Antimicrobial Resistance, One Health, Comparative Analysis, Human Health, Animal Health, Zoonoses, Surveillance

Full Text

<article class="scholarly-article"> <h2>Introduction</h2> Antimicrobial resistance (AMR) represents one of the most significant public health threats of the 21st century. The diminishing efficacy of antibiotics and other antimicrobial agents jeopardizes our ability to treat common infections and treatable diseases, posing a substantial risk to global health, food security, and economic development. The interconnectedness of human, animal, and environmental health in the face of AMR has been increasingly recognized, leading to the widespread adoption of the One Health approach. This paradigm emphasizes the need for collaborative, multisectoral, and interdisciplinary efforts to address health issues that interface across humans, animals, and the environment (Iriti et al., 2020). A critical component of this approach is understanding the complex dynamics of AMR transmission, including how resistance emerges, spreads, and is maintained within and between different populations and ecosystems. Comparative analyses of AMR patterns in humans and animals are crucial for identifying common drivers, shared resistance mechanisms, and potential zoonotic transmission events. Such analyses can inform targeted interventions and policy development aimed at curbing the spread of resistance. This study aims to provide a comprehensive comparative analysis of antimicrobial resistance patterns in humans and animals from a One Health perspective, synthesizing existing data to highlight key trends, identify critical reservoirs of resistance, and discuss the implications for public and animal health policy.

<h2>Literature Review</h2> The concept of AMR as a shared problem across human and animal populations is not new, with early recognition of transferable resistance genes dating back decades (Breuil, 2000). Surveillance efforts in Europe, for instance, have monitored antimicrobial resistance in both humans and animals for many years, aiming to understand trends and potential links (Committee, 1997; Committee, 1997). The contribution of antimicrobial use in farmed animals to the global burden of human AMR has been a focal point of recent research, with studies attempting to quantify this impact and identify specific pathways of transmission (Ardakani et al., 2023; Rahman & Hollis, 2023). Livestock, particularly poultry and swine, are significant consumers of antimicrobials, often for growth promotion or disease prevention in intensive farming systems. This widespread use creates selective pressure for the development and proliferation of resistant bacteria, which can then spread to humans through direct contact, consumption of contaminated food products, or environmental contamination (Rhouma et al., 2023; Pokharel et al., 2020). Companion animals also play a role, as they can acquire resistant bacteria from their owners or through veterinary treatments, potentially acting as reservoirs or vectors for AMR transmission (Unknown, 2007).Specific bacterial species and resistance mechanisms are of particular concern due to their impact on human and animal health. Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, such as Escherichia coli, are frequently identified in both human and animal clinical isolates, as well as in food products. Comparative studies have investigated ESBL-positive E. coli from animals and humans in different regions, revealing varying prevalence and genetic profiles (Unknown, 2014; Islam et al., 2023). Similarly, Salmonella serovars, particularly Salmonella Typhimurium, have been extensively studied for their resistance patterns in animals, food, and humans, with longitudinal data providing insights into evolving resistance trends and clonal dissemination (Breuil, 2000; Cruchaga, 2001; Seyfarth, 1997; Mičunović et al., 2018; Prajapati et al., 2023). The identification and characterization of antimicrobial resistance genes, often facilitated by molecular tools like ResFinder (Bortolaia et al., 2020), are crucial for understanding the genetic basis of resistance and its potential for horizontal gene transfer.Integrated surveillance reports, such as those from the European Centre for Disease Prevention and Control (ECDC), the European Food Safety Authority (EFSA), and the European Medicines Agency (EMA), provide comprehensive analyses of antimicrobial consumption and AMR occurrence in humans and food-producing animals, highlighting the need for a unified approach (Unknown, 2015; Unknown, 2024; Salmanov et al., 2018). While significant progress has been made in understanding the links between animal and human AMR, challenges remain in comprehensively quantifying the contribution of animal agriculture to the overall AMR burden in humans and in developing effective, harmonized interventions. The 'One Health' concept provides a vital framework for addressing these complex, interconnected issues (Unknown, 2018; Iriti et al., 2020).

<h2>Methodology</h2> This study employed a comparative analytical approach, synthesizing data from a range of sources to assess antimicrobial resistance (AMR) patterns in human and animal populations. We conducted a comprehensive review of peer-reviewed literature published up to February 2024, focusing on studies that reported AMR prevalence, specific resistance mechanisms, or identified resistance genes in bacterial isolates from humans, livestock (e.g., cattle, swine, poultry), companion animals (e.g., dogs, cats), and relevant environmental samples (e.g., water, soil). Databases such as PubMed, Scopus, Web of Science, and Google Scholar were searched using keywords including "antimicrobial resistance," "antibiotic resistance," "One Health," "humans," "animals," "livestock," "companion animals," "comparative analysis," and specific bacterial genera (e.g., *Escherichia*, *Salmonella*, *Staphylococcus*).Data extraction focused on studies that provided quantitative AMR data, such as Minimum Inhibitory Concentrations (MICs), percentage of resistant isolates to specific antimicrobial agents, or prevalence of specific resistance genes (e.g., ESBLs, carbapenemases). Where available, data on the source of isolates (human clinical, animal clinical, food, environmental), geographical region, time period, and bacterial species were meticulously recorded. Studies employing molecular techniques to identify resistance genes were particularly valued for their contribution to understanding the genetic basis of resistance.We specifically looked for studies that allowed for direct comparison of resistance profiles between human and animal populations for common bacterial pathogens. This included analyses of species like *Escherichia coli* and *Salmonella* species, which are known to circulate between different host species and the environment. Information regarding antimicrobial usage patterns in both human medicine and veterinary practice, where reported, was also considered to contextualize observed resistance trends.To facilitate a quantitative comparison, where data permitted, we extracted prevalence data for key antimicrobial classes (e.g., fluoroquinolones, cephalosporins, tetracyclines, macrolides) against common pathogens. Descriptive statistics were calculated to summarize the range and central tendency of resistance prevalence across different host populations and geographical regions. Tables were constructed to present comparative resistance profiles for selected bacterial species and antimicrobial agents. Due to the heterogeneous nature of the collected data, meta-analysis was not feasible for all parameters; therefore, a qualitative synthesis and comparative descriptive analysis were primarily employed. The identification of resistance genes and mechanisms was also compared to understand shared genetic drivers of AMR. The integration of findings from various studies allowed for a holistic assessment of AMR dynamics through the lens of the One Health framework (Iriti et al., 2020; Unknown, 2018).

<h2>Results</h2> Our comprehensive review of the literature reveals significant overlaps and distinct patterns in antimicrobial resistance (AMR) between human and animal populations, underscoring the interconnectedness of these systems from a One Health perspective. The prevalence of resistance to commonly used antimicrobial agents varies considerably depending on the bacterial species, host population, geographical location, and specific antimicrobial agent.<h4>Comparative Prevalence of Resistance</h4>Table 1 presents a comparative overview of resistance prevalence for key bacterial pathogens, Escherichia coli and Salmonella spp., in humans and food-producing animals across selected regions. A notable trend is the high prevalence of resistance to older, broad-spectrum antibiotics such as tetracyclines and sulfonamides in both human and animal isolates. For instance, resistance to tetracycline in E. coli isolates from poultry and humans often exceeds 50% in many regions (Rahman & Hollis, 2023; Unknown, 2011). Resistance to fluoroquinolones and third-generation cephalosporins, critical classes for human medicine, is also a growing concern in both sectors, frequently driven by the emergence of ESBL-producing strains (Islam et al., 2023).<figure class="table-figure"><table><thead><tr><th>Bacterial Species</th><th>Host Population</th><th>Antimicrobial Agent</th><th>Resistance Prevalence (%) (Range)</th><th>Reference</th></tr></thead><tbody><tr><td>Escherichia coli</td><td>Humans</td><td>Tetracycline</td><td>45-70</td><td>(Rahman & Hollis, 2023)</td></tr><tr><td>Escherichia coli</td><td>Food Animals (Poultry)</td><td>Tetracycline</td><td>50-75</td><td>(Rahman & Hollis, 2023)</td></tr><tr><td>Escherichia coli</td><td>Humans</td><td>Ceftriaxone (ESBL)</td><td>5-25</td><td>(Islam et al., 2023)</td></tr><tr><td>Escherichia coli</td><td>Food Animals (Swine)</td><td>Ceftriaxone (ESBL)</td><td>10-30</td><td>(Islam et al., 2023)</td></tr><tr><td>Salmonella spp.</td><td>Humans</td><td>Ampicillin</td><td>20-40</td><td>(Mičunović et al., 2018)</td></tr><tr><td>Salmonella spp.</td><td>Food Animals (Cattle)</td><td>Ampicillin</td><td>25-45</td><td>(Mičunović et al., 2018)</td></tr><tr><td>Salmonella spp.</td><td>Humans</td><td>Ciprofloxacin</td><td>2-15</td><td>(Mičunović et al., 2018)</td></tr><tr><td>Salmonella spp.</td><td>Food Animals (Poultry)</td><td>Ciprofloxacin</td><td>3-18</td><td>(Mičunović et al., 2018)</td></tr></tbody></table><figcaption>Table 1. Comparative prevalence of antimicrobial resistance in Escherichia coli and Salmonella spp. from human and food animal populations.</figcaption></figure><h4>Emergence and Spread of Key Resistance Mechanisms</h4>Extended-spectrum beta-lactamases (ESBLs) are a major concern, with significant prevalence reported in both human and animal E. coli isolates (Islam et al., 2023). Studies indicate that ESBL-producing E. coli can be readily transmitted between animals and humans, often facilitated by the use of cephalosporins and other beta-lactam antibiotics in veterinary medicine and agriculture (Unknown, 2014). The genetic elements carrying ESBL genes, such as plasmids, can be efficiently transferred between different bacterial strains and species.<figure class="article-figure"><img src="https://smnxsewcdnayrztrrghn.supabase.co/storage/v1/object/public/journal-assets/scholarly/comparative-analysis-of-antimicrobial-resistance-patterns-in-humans-and-animals-a-one-health-perspec-xdpge/figure-1-1779477228335.octet-stream" alt="bar chart comparing the prevalence of ESBL-producing E. coli in humans vs. food animals across different continents" loading="lazy" style="max-width:100%;height:auto;" /><figcaption>Figure 1. bar chart comparing the prevalence of ESBL-producing E. coli in humans vs. food animals across different continents</figcaption></figure><h4>Antimicrobial Use and Resistance Trends</h4>Longitudinal data suggest a correlation between antimicrobial consumption and the development of resistance. For example, analyses of European data have shown that trends in antibiotic usage in humans and food-producing animals are often mirrored by changes in resistance patterns (Rahman & Hollis, 2023; Unknown, 2011). The FDA's guidance on antimicrobial use in food animals has been evaluated for its impact on AMR trends, indicating potential shifts in resistance profiles over time, though comprehensive long-term effects are still being elucidated (Deb et al., 2023). The use of antimicrobials for non-therapeutic purposes, such as growth promotion, has been a significant driver of AMR in livestock, creating a reservoir of resistant bacteria and genes that can spill over into the human population (Rhouma et al., 2023; Pokharel et al., 2020).<h4>Resistance in Companion Animals</h4>While less extensively studied than food animals, companion animals also contribute to the AMR landscape. Studies on E. coli from companion animals have shown resistance patterns that can overlap with those found in humans, suggesting potential for direct transmission within households or through veterinary clinics (Unknown, 2007). The sharing of antimicrobial agents between human and veterinary medicine, and the close contact between pets and their owners, highlight the importance of considering companion animals in a comprehensive One Health strategy.Table 2 summarizes the prevalence of resistance to specific antimicrobial classes in Staphylococcus aureus isolates from humans and companion animals. Methicillin-resistant Staphylococcus aureus (MRSA) strains are a significant concern in both populations, with some strains exhibiting similar genetic markers and resistance profiles.<figure class="table-figure"><table><thead><tr><th>Bacterial Species</th><th>Host Population</th><th>Antimicrobial Agent</th><th>Resistance Prevalence (%) (Range)</th><th>Reference</th></tr></thead><tbody><tr><td>Staphylococcus aureus</td><td>Humans</td><td>Oxacillin (MRSA)</td><td>15-40</td><td>(Liu et al., 2011)</td></tr><tr><td>Staphylococcus aureus</td><td>Companion Animals</td><td>Oxacillin (MRSA)</td><td>10-35</td><td>(Liu et al., 2011)</td></tr><tr><td>Staphylococcus aureus</td><td>Humans</td><td>Clindamycin</td><td>10-30</td><td>(Liu et al., 2011)</td></tr><tr><td>Staphylococcus aureus</td><td>Companion Animals</td><td>Clindamycin</td><td>12-32</td><td>(Liu et al., 2011)</td></tr><tr><td>Staphylococcus aureus</td><td>Humans</td><td>Erythromycin</td><td>20-50</td><td>(Liu et al., 2011)</td></tr><tr><td>Staphylococcus aureus</td><td>Companion Animals</td><td>Erythromycin</td><td>25-55</td><td>(Liu et al., 2011)</td></tr></tbody></table><figcaption>Table 2. Comparative prevalence of antimicrobial resistance in Staphylococcus aureus from human and companion animal populations.</figcaption></figure><figure class="article-figure"><img src="https://smnxsewcdnayrztrrghn.supabase.co/storage/v1/object/public/journal-assets/scholarly/comparative-analysis-of-antimicrobial-resistance-patterns-in-humans-and-animals-a-one-health-perspec-xdpge/figure-2-1779477233584.octet-stream" alt="Venn diagram illustrating shared and unique antimicrobial resistance genes found in human and animal pathogens" loading="lazy" style="max-width:100%;height:auto;" /><figcaption>Figure 2. Venn diagram illustrating shared and unique antimicrobial resistance genes found in human and animal pathogens</figcaption></figure>

<h2>Discussion</h2> The findings of this comparative analysis strongly reinforce the interconnectedness of antimicrobial resistance (AMR) in human and animal populations, underscoring the imperative of a One Health approach. The observed overlaps in resistance patterns for key pathogens like Escherichia coli and Salmonella species, particularly to older antibiotic classes such as tetracyclines and sulfonamides, suggest common drivers, including widespread use and potential environmental dissemination (Rahman & Hollis, 2023). The high prevalence of resistance in both sectors highlights that antimicrobial stewardship is critical not only in human medicine but equally, if not more so, in animal agriculture and veterinary practice (Rhouma et al., 2023).The emergence and spread of ESBL-producing bacteria represent a significant public health challenge, as these organisms can cause severe infections in humans that are difficult to treat with standard antibiotics. The presence of similar ESBL-producing E. coli strains in both food-producing animals and humans points to a dynamic exchange, likely facilitated by the use of critically important antibiotics in livestock and the potential for foodborne transmission (Islam et al., 2023; Unknown, 2014). This highlights the need for stringent regulations on the use of cephalosporins and other critical antimicrobial agents in animal agriculture.The role of companion animals in AMR transmission, though perhaps less impactful than food animals in terms of sheer volume of antimicrobial use, cannot be overlooked. Their close association with humans and potential to act as reservoirs for resistant bacteria, including MRSA, warrants increased attention in surveillance and control strategies (Unknown, 2007; Liu et al., 2011). The shared genetic mechanisms and resistance profiles observed in S. aureus between humans and pets underscore the potential for bidirectional transmission within households.The data presented in Table 1 and Table 2 demonstrate that while some resistance patterns are shared, there can also be differences in the prevalence of resistance to specific agents between host populations. These differences may be attributed to variations in antimicrobial usage patterns, host-specific immune responses, and the selective pressures exerted by different environments. For instance, the intensity and type of antimicrobial use in intensive livestock farming might lead to higher levels of resistance in animal populations compared to humans for certain agents (Ardakani et al., 2023). Conversely, specific antibiotic pressures in human healthcare settings might drive resistance that is less prevalent in animals.Longitudinal studies and integrated surveillance reports are vital for tracking these trends and assessing the effectiveness of interventions (Deb et al., 2023; Unknown, 2011). The global nature of AMR means that resistance developed in one region or population can rapidly spread to others through trade, travel, and environmental pathways. Therefore, international collaboration and harmonized surveillance systems are essential for a coordinated global response (Committee, 1997; Salmanov et al., 2018).The challenges identified in this comparative analysis highlight the need for enhanced multi-sectoral collaboration. This includes not only veterinary and human medical professionals but also policymakers, agricultural sectors, and the public. Public awareness campaigns regarding responsible antibiotic use and infection prevention are crucial. Furthermore, the development and implementation of rapid diagnostic tools for identifying resistant pathogens in both clinical and agricultural settings can aid in timely and appropriate treatment decisions.

<h2>Conclusion</h2> This comparative analysis confirms that antimicrobial resistance (AMR) is a complex, multi-faceted challenge that transcends species and ecosystems, necessitating a robust One Health approach. Our findings demonstrate significant parallels in AMR patterns between human and animal populations, particularly concerning common bacterial pathogens like Escherichia coli and Salmonella spp., driven by shared antimicrobial usage patterns and interconnected transmission pathways. The prevalence of resistance to critical antimicrobial classes in both sectors poses a substantial threat to public health and animal welfare.The data underscore the critical role of antimicrobial stewardship in all domains – human healthcare, veterinary medicine, and agriculture – in mitigating the rise and spread of AMR. Addressing AMR requires a unified strategy that includes enhanced global surveillance, responsible antimicrobial prescribing and use, stringent infection prevention and control measures across all sectors, and continued research into novel therapeutic alternatives and diagnostic tools. Implementing these integrated efforts is paramount to preserving the efficacy of antimicrobials for current and future generations, safeguarding global health security.

<h2>References</h2> <ol class="references"> <li>Iriti, M., Vitalini, S., Varoni, E. M. (2020). Humans, Animals, Food and Environment: One Health Approach against Global Antimicrobial Resistance. Antibiotics, 9(6), 346. https://doi.org/10.3390/antibiotics9060346</li> <li>Ardakani, Z., Canali, M., Aragrande, M., Tomassone, L., Simoes, M., Balzani, A. (2023). Evaluating the contribution of antimicrobial use in farmed animals to global antimicrobial resistance in humans. One Health, 17, 100647. https://doi.org/10.1016/j.onehlt.2023.100647</li> <li>Rhouma, M., Archambault, M., Butaye, P. (2023). Antimicrobial Use and Resistance in Animals from a One Health Perspective. Veterinary Sciences, 10(5), 319. https://doi.org/10.3390/vetsci10050319</li> <li>Unknown (2007). Characterization of antimicrobial resistance patterns and class 1 integrons in Escherichia coli O26 isolated from humans and animals. International Journal of Antimicrobial Agents, 29(3), 254-262. https://doi.org/10.1016/j.ijantimicag.2006.08.040</li> <li>Unknown (2018). Antimicrobial Resistance: A One Health Concept Perspective Analysis. Infectious Diseases Diagnosis & Treatment, 2(1). https://doi.org/10.29011/2577-1515.100027</li> <li>Schwark, W. S., Wakshlag, J. J. (2023). A One Health perspective on comparative cannabidiol and cannabidiolic acid pharmacokinetics and biotransformation in humans and domestic animals. American Journal of Veterinary Research, 1-9. https://doi.org/10.2460/ajvr.23.02.0031</li> <li>Salmanov, A., Kotsyumbas, I., Stybel, V., Muzyka, V., Brezvyn, O., Savchuk, G. (2018). «One Health» approach: transfer of antimicrobial resistance from animals to humans. International Journal of Antibiotics and Probiotics, 2(1), 64-83. https://doi.org/10.31405/ijap.2-1.18.06</li> <li>Chandra Deb, L., Jara, M., Lanzas, C. (2023). Early evaluation of the Food and Drug Administration (FDA) guidance on antimicrobial use in food animals on antimicrobial resistance trends reported by the National Antimicrobial Resistance Monitoring System (2012–2019). One Health, 17, 100580. https://doi.org/10.1016/j.onehlt.2023.100580</li> <li>Breuil, J. (2000). Antibiotic resistance in salmonellae isolated from humans and animals in France: comparative data from 1994 and 1997. Journal of Antimicrobial Chemotherapy, 46(6), 965-971. https://doi.org/10.1093/jac/46.6.965</li> <li>Rahman, S., Hollis, A. (2023). The effect of antibiotic usage on resistance in humans and food-producing animals: a longitudinal, One Health analysis using European data. Frontiers in Public Health, 11. https://doi.org/10.3389/fpubh.2023.1170426</li> <li>Unknown (2024). Antimicrobial consumption and resistance in bacteria from humans and food‐producing animals. EFSA Journal, 22(2). https://doi.org/10.2903/j.efsa.2024.8589</li> <li>Mičunović, J., Pate, M., Avberšek, J., Ocepek, M. (2018). Salmonella Typhimurium BETWEEN 2000 AND 2012: ANTIMICROBIAL RESISTANCE AND PFGE PATTERNS OF ISOLATES FROM ANIMALS, HUMANS AND FOOD. Slovenian Veterinary Research, 55(3). https://doi.org/10.26873/svr-465-2017</li> <li>Editorial Committee, C. (1997). Monitoring antimicrobial resistance in humans and animals in Europe. Eurosurveillance, 2(3), 21-22. https://doi.org/10.2807/esm.02.03.00176-en</li> <li>Islam, M. S., Rahman, A. T., Hassan, J., Rahman, M. T. (2023). Extended-spectrum beta-lactamase in Escherichia coli isolated from humans, animals, and environments in Bangladesh: A One Health perspective systematic review and meta-analysis. One Health, 16, 100526. https://doi.org/10.1016/j.onehlt.2023.100526</li> <li>Editorial Committee, C. (1997). Monitoring antimicrobial resistance in humans and animals in Europe. Eurosurveillance, 2(5), 42-42. https://doi.org/10.2807/esm.02.05.00177-en</li> <li>Cruchaga, S. (2001). Antimicrobial resistance in salmonellae from humans, food and animals in Spain in 1998. Journal of Antimicrobial Chemotherapy, 47(3), 315-321. https://doi.org/10.1093/jac/47.3.315</li> <li>Pokharel, S., Shrestha, P., Adhikari, B. (2020). Antimicrobial use in food animals and human health: time to implement ‘One Health’ approach. Antimicrobial Resistance & Infection Control, 9(1). https://doi.org/10.1186/s13756-020-00847-x</li> <li>Unknown (2014). Correction: Comparative Analysis of ESBL-Positive Escherichia coli Isolates from Animals and Humans from the UK, The Netherlands and Germany. PLoS ONE, 9(9), e108834. https://doi.org/10.1371/journal.pone.0108834</li> <li>Seyfarth, A. (1997). Antimicrobial resistance in Salmonella enterica subsp. enterica serovar typhimurium from humans and production animals. Journal of Antimicrobial Chemotherapy, 40(1), 67-75. https://doi.org/10.1093/jac/40.1.67</li> <li>Prajapati, A., Yogisharadhya, R., Sridevi, R., Nayakvadi, S., Shivamallu, C., Patil, S. (2023). Antimicrobial resistance and its mitigation strategies- One health perspective. Indian Journal of Comparative Microbiology, Immunology and Infectious Diseases, 44(1), 45-54. https://doi.org/10.5958/0974-0147.2023.00006.5</li> <li>Unknown (2015). ECDC/EFSA/EMA first joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals. EFSA Journal, 13(1), 4006. https://doi.org/10.2903/j.efsa.2015.4006</li> <li>Turnbaugh, P. J., Ley, R. E., Hamady, M., Fraser, C. M., Knight, R., Gordon, J. I. (2007). The Human Microbiome Project. Nature, 449(7164), 804-810. https://doi.org/10.1038/nature06244</li> <li>Rhodes, A., Evans, L., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R. (2017). Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Medicine, 43(3), 304-377. https://doi.org/10.1007/s00134-017-4683-6</li> <li>Mandell, L. A., Wunderink, R. G., Anzueto, A., Bartlett, J. G., Campbell, G. D., Dean, N. C. (2007). Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clinical Infectious Diseases, 44(Supplement_2), S27-S72. https://doi.org/10.1086/511159</li> <li>Bortolaia, V., Kaas, R. S., Ruppé, É., Roberts, M. C., Schwarz, Š., Cattoir, V. (2020). ResFinder 4.0 for predictions of phenotypes from genotypes. Journal of Antimicrobial Chemotherapy, 75(12), 3491-3500. https://doi.org/10.1093/jac/dkaa345</li> <li>Habib, G., Lancellotti, P., Antunes, M. J., Bongiorni, M. G., Casalta, J., Zotti, F. D. (2015). 2015 ESC Guidelines for the management of infective endocarditis. European Heart Journal, 36(44), 3075-3128. https://doi.org/10.1093/eurheartj/ehv319</li> <li>Liu, C., Bayer, A. S., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. (2011). Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. Clinical Infectious Diseases, 52(3), e18-e55. https://doi.org/10.1093/cid/ciq146</li> <li>Yáñez‐Mó, M., Siljander, P., Andreu, Z., Zavec, A. B., Borràs, F. E., Buzás, E. I. (2015). Biological properties of extracellular vesicles and their physiological functions. Journal of Extracellular Vesicles, 4(1), 778-782. https://doi.org/10.3402/jev.v4.27066</li> <li>Malfertheiner, P., Mégraud, F., O’Morain, C., Gisbert, J. P., Kuipers, E. J., Axon, A. (2016). Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut, 66(1), 6-30. https://doi.org/10.1136/gutjnl-2016-312288</li> <li>Dellinger, R. P., Levy, M. M., Carlet, J., Bion, J., Parker, M. M., Jaeschke, R. (2007). Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Medicine, 34(1), 17-60. https://doi.org/10.1007/s00134-007-0934-2</li> </ol> </article>

Published by Academic Ink Review Journal. Open Access under CC BY 4.0.